Cargando…
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer
Triple-negative breast cancer (TNBC) lacks prognostic and predictive markers. Here, we use high-throughput phosphoproteomics to build a functional TNBC taxonomy. A cluster of 159 phosphosites is upregulated in relapsed cases of a training set (n = 34 patients), with 11 hyperactive kinases accounting...
Autores principales: | Zagorac, Ivana, Fernandez-Gaitero, Sara, Penning, Renske, Post, Harm, Bueno, Maria J., Mouron, Silvana, Manso, Luis, Morente, Manuel M., Alonso, Soledad, Serra, Violeta, Muñoz, Javier, Gómez-López, Gonzalo, Lopez-Acosta, Jose Francisco, Jimenez-Renard, Veronica, Gris-Oliver, Albert, Al-Shahrour, Fatima, Piñeiro-Yañez, Elena, Montoya-Suarez, Jose Luis, Apala, Juan V., Moreno-Torres, Amalia, Colomer, Ramon, Dopazo, Ana, Heck, Albert J. R., Altelaar, Maarten, Quintela-Fandino, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115463/ https://www.ncbi.nlm.nih.gov/pubmed/30158526 http://dx.doi.org/10.1038/s41467-018-05742-z |
Ejemplares similares
-
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
por: Quintela-Fandino, Miguel, et al.
Publicado: (2019) -
Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance
por: Manso, Luis, et al.
Publicado: (2016) -
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
por: Mouron, Silvana, et al.
Publicado: (2021) -
Proteomics and
Phosphoproteomics Profiling of Drug-Addicted
BRAFi-Resistant Melanoma Cells
por: Li, Bohui, et al.
Publicado: (2021) -
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
por: Mouron, S., et al.
Publicado: (2022)